| Date | Time | Source | Headline | Symbol | Company |
| 06/15/2024 | 10:00AM | UK Regulatory | Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma | LSE:0QQ6 | Roche Holding Ag |
| 06/10/2024 | 1:05AM | UK Regulatory | Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization | LSE:0QQ6 | Roche Holding Ag |
| 06/10/2024 | 1:00AM | UK Regulatory | European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer | LSE:0QQ6 | Roche Holding Ag |
| 06/07/2024 | 10:40AM | UK Regulatory | Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk | LSE:0QQ6 | Roche Holding Ag |
| 05/29/2024 | 1:00AM | UK Regulatory | FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation | LSE:0QQ6 | Roche Holding Ag |
| 05/27/2024 | 1:00AM | UK Regulatory | Changes to the Roche Enlarged Corporate Executive Committee | LSE:0QQ6 | Roche Holding Ag |
| 05/27/2024 | 1:00AM | UK Regulatory | Wechsel in der erweiterten Konzernleitung von Roche | LSE:0QQ6 | Roche Holding Ag |
| 05/22/2024 | 1:00AM | UK Regulatory | Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk | LSE:0QQ6 | Roche Holding Ag |
| 05/21/2024 | 1:00AM | UK Regulatory | FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation | LSE:0QQ6 | Roche Holding Ag |
| 05/16/2024 | 1:00AM | UK Regulatory | [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity | LSE:0QQ6 | Roche Holding Ag |
| 05/15/2024 | 1:00AM | UK Regulatory | Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer | LSE:0QQ6 | Roche Holding Ag |
| 04/24/2024 | 1:00AM | UK Regulatory | [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 | LSE:0QQ6 | Roche Holding Ag |
| 04/24/2024 | 1:00AM | UK Regulatory | [Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte | LSE:0QQ6 | Roche Holding Ag |
| 04/19/2024 | 1:00AM | UK Regulatory | FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer | LSE:0QQ6 | Roche Holding Ag |
| 04/17/2024 | 2:00AM | UK Regulatory | Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS | LSE:0QQ6 | Roche Holding Ag |
| 04/15/2024 | 1:00AM | UK Regulatory | [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study | LSE:0QQ6 | Roche Holding Ag |
| 04/11/2024 | 1:00AM | UK Regulatory | Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis | LSE:0QQ6 | Roche Holding Ag |
| 03/26/2024 | 12:45PM | UK Regulatory | Roche receives FDA approval for the first molecular test to screen for malaria in blood donors | LSE:0QQ6 | Roche Holding Ag |
| 03/12/2024 | 8:30AM | UK Regulatory | Assemblée générale 2024 de Roche | LSE:0QQ6 | Roche Holding Ag |
| 03/12/2024 | 8:30AM | UK Regulatory | Roche Generalversammlung 2024 | LSE:0QQ6 | Roche Holding Ag |
| 03/12/2024 | 8:30AM | UK Regulatory | Roche Annual General Meeting 2024 | LSE:0QQ6 | Roche Holding Ag |
| 03/05/2024 | 7:30AM | UK Regulatory | Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care | LSE:0QQ6 | Roche Holding Ag |
| 02/25/2024 | 2:00PM | UK Regulatory | New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies | LSE:0QQ6 | Roche Holding Ag |
| 02/16/2024 | 11:24AM | UK Regulatory | FDA approves Xolair as first and only medicine for children and adults with one or more food allergies | LSE:0QQ6 | Roche Holding Ag |
| 02/01/2024 | 1:03AM | UK Regulatory | New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO) | LSE:0QQ6 | Roche Holding Ag |
| 02/01/2024 | 1:00AM | UK Regulatory | [Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline | LSE:0QQ6 | Roche Holding Ag |
| 02/01/2024 | 1:00AM | UK Regulatory | [Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER) | LSE:0QQ6 | Roche Holding Ag |
| 02/01/2024 | 1:00AM | UK Regulatory | [Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19 | LSE:0QQ6 | Roche Holding Ag |
| 10/23/2023 | 7:18AM | IH Market News | Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more | LSE:0QQ6 | Roche Holding Ag |